

Supplementary Materials for

GPR40 modulates epileptic seizure and NMDA receptor function

Yong Yang, Xin Tian, Demei Xu, Fangshuo Zheng, Xi Lu, Yanke Zhang, Yuanlin Ma, Yun Li, Xin Xu, Binglin Zhu*, Xuefeng Wang*

*Corresponding author. Email: zhubinglin0311@163.com (B.Z.); xfyp@163.com (X.W.)

Published 17 October 2018, *Sci. Adv.* **4**, eaau2357 (2018)
DOI: 10.1126/sciadv.aau2357

This PDF file includes:

- Fig. S1. Immunofluorescent labeling of GPR40 in nonepileptic brain tissues.
- Fig. S2. Immunofluorescent labeling of GPR40 in epileptic tissues.
- Fig. S3. Immunofluorescence intensity of GPR40 in epileptic and nonepileptic brain tissues.
- Fig. S4. GPR40 has no effect on PPR for NMDA-mediated EPSCs.
- Fig. S5. GPR40 regulates spine density.
- Table S1. Clinical characteristics of epileptic patients in this study.
- Table S2. Clinical characteristics of control individuals with brain trauma.

Supplementary Materials




Fig. S1. Immunofluorescent labeling of GPR40 in nonepileptic brain tissues. (A) GPR40 localization in the hippocampus. **(B and C)** In hippocampal tissue from healthy mice, GPR40 colocalized with Map2 and with PSD95 but not with GFAP. **(D and E)** In the temporal neocortices from non-epileptic patients, GPR40 colocalized with Map2 and with PSD95 but not with GFAP (scale bar=50 μm).




Fig. S2. Immunofluorescent labeling of GPR40 in epileptic tissues. (A and B) In hippocampal tissue from a mouse TLE model, GPR40 colocalized with Map2 and with PSD95 but not with GFAP. **(C and D)** In the temporal neocortices from TLE patients, GPR40 colocalized with Map2 and with PSD95 but not with GFAP (scale bar=50 μm).




Fig. S3. Immunofluorescence intensity of GPR40 in epileptic and non-epileptic brain tissues. (A) GPR40 immunoreactivity was increased in the hippocampal CA1 region of mice from the KA-induced model compared with controls (Control n=93, Epilepsy n=73). (B) GPR40 immunoreactivity was increased in the neocortex of TLE patients compared with non-epileptic controls (Control n=74, Epilepsy n=62). Data are shown as the means \pm s.e.m.; Student's t-test, *** $p < 0.001$.




Fig. S4. GPR40 has no effect on PPR for NMDA-mediated EPSCs. (A and B) Representative traces of the PPR for NMDA-mediated EPSCs and summary of the PPR among the groups. For the analysis, n=6 in each group. The effect of each treatment was normalized to the baseline; error bars represent the mean \pm s.e.m.; n.s., not significant, paired t-test.




Fig. S5. GPR40 regulates spine density. (A) Representative confocal images showing the spine density on cultured hippocampal neurons after treatment with 0.1% DMSO, GW9508 (20 μ M) or GW1100 (20 μ M), scale bar = 10 μ m. (B) The summarized result of the spine density (DMSO n=24, GW9508 n=23, GW1100 n=21, one-way ANOVA followed by Tukey's test, ***p < 0.001).

Table S1. Clinical characteristics of epileptic patients in this study.

Case	Gender/Age (years)	Course (years)	AEDs before surgery	Resection tissue	Neuropathological diagnosis
EP 1	M/25	11	PB, VPA, LTG	RTN	G, NL
EP 2	F/30	11	VPA, PB, PHT, TPM	LTN	G, NL
EP 3	M/18	15	PHT, PB, CBZ, VPA	RTN	G
EP 4	M/22	18	VPA, CBZ, PHT	LTN	NL, G
EP 5	F/26	7	CBZ, VPA, TPM	LTN	G
EP 6	F/36	10	PB, CBZ, VPA, OXC	RTN	NL, G
EP 7	F/12	5	CBZ, TPM, LTG,	LTN	NL, G
EP 8	F/21	8	TPM, VPA, CBZ	LTN	G
EP 9	F/23	6	TPM, CBZ, VPA	RTN	G
EP 10	F/20	7	VPA, OXC, PB	RTN	NL, G
EP 11	M/9	6	CBZ, PB, LTG	LTN	NL
EP 12	F/33	15	OXC, CBZ, TPM, PB	LTN	NL, G
EP 13	F/14	5	CBZ, LTG, TPM,	RTN	NL,
EP 14	F/18	13	CBZ, VPA, TPM	LTN	NL, G
EP 15	F/25	14	VPA, CBZ, LTG	LTN	NL
EP 16	F/24	6	CBZ, VPA, TPM	LTN	G
EP 17	M/20	7	VPA, TPM, PB	RTN	G, NL
EP 18	F/14	9	VPA, CBZ, PB	RTN	NL, G
EP 19	M/21	6	CBZ, VPA, TPM, PHT	RTN	NL
EP 20	M/39	10	CBZ, VPA, TPM	LTN	NL, G

EP=epilepsy patients; C=control; F=female; M=male; AEDs=antiepileptic drugs; CBZ=carbamazepine; VPA=valproate; TPM= topiramate; PHT=phenytoin; PB=phenobarbital; LTG=lamotrigine; OXC=oxcarbazepine; LTN=left temporal neocortex; RTN=right temporal neocortex; G=gliosis; NL=neuron loss.

Table S2. Clinical characteristics of control individuals with brain trauma.

Case	Gender/Age (years)	Mechanism of injury	GCS score	Time to surgical intervention (hours)	Resection tissue	Neuropathological diagnosis
TBI 1	M/11	MVA	7	15	LTN	N
TBI 2	F/38	Fall	7	20	LTN	N
TBI 3	M/40	MVA	5	15	LTN	N
TBI 4	F/34	Stumble	8	17	LTN	N
TBI 5	M/30	MVA	6	11	RTN	N
TBI 6	F/17	MVA	7	18	RTN	N
TBI 7	M/11	MVA	9	22	RTN	N
TBI 8	M/25	MVA	5	12	RTN	N
TBI 9	F/8	Stumble	6	15	LTN	N
TBI 10	M/20	MVA	7	19	RTN	N

TBI= traumatic brain injury; F=female; M=male; MVA=motor vehicle accident; GCS= Glasgow Coma Scale; LTN=left temporal neocortex; RTN=right temporal neocortex; N=relative normal.